Moreover, intraarticular angiotensin II administration also induced inflammatory parameters, that are also the clinical features of gout in humans, such as edema, neutrophil infiltration and IL-1β release, all of which were prevented by specific AT2R antagonism. Here, IL1B is linked to gout.